Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Sara L. Revolinski PharmD

Adjunct Assistant Professor

Institution: Medical College of Wisconsin
Department: School of Pharmacy Administration
Division: Administration
Program: Administration

Publications (11)

  • Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs? (Revolinski SL, Doern CD) J Clin Microbiol 2021 Mar 19;59(4) PMID: 33536296 PMCID: PMC8092730 SCOPUS ID: 2-s2.0-85102931996 02/05/2021       1 Citation
  • Impact of an Antimicrobial Stewardship Program Pharmacist During Microbiology Rounds. (Sapozhnikov J, Huang A, Revolinski S, Ledeboer NA, Buchan BW) Am J Clin Pathol 2021 Feb 11;155(3):455-460 PMID: 32949141 SCOPUS ID: 2-s2.0-85102099001 09/20/2020       3 Citations
  • Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Hosts. (Revolinski S, Munoz-Price LS) Clin Infect Dis 2021 Jun 15;72(12):2247 PMID: 32275059 SCOPUS ID: 2-s2.0-85103344088 04/11/2020       2 Citations
  • Antibiotic Duration and Outcome Complications for Surgical Site Infection Prevention in Traumatic Mandible Fracture. (Zein Eddine SB, Cooper-Johnson K, Ericksen F, Brookes CC, Peppard WJ, Revolinski SL, Carver TW) J Surg Res 2020 Mar;247:524-529 PMID: 31668431 SCOPUS ID: 2-s2.0-85074440328 11/02/2019       9 Citations
  • Clostridioides difficile in transplant patients: early diagnosis, treatment, and prevention. (Revolinski SL, Munoz-Price LS) Curr Opin Infect Dis 2019 Aug;32(4):307-313 PMID: 31116134 SCOPUS ID: 2-s2.0-85069234375 05/23/2019       2 Citations
  • Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention. (Revolinski SL, Munoz-Price LS) Clin Infect Dis 2019 May 30;68(12):2144-2153 PMID: 30281082 SCOPUS ID: 2-s2.0-85064842624 10/04/2018       59 Citations
  • A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study. (Lat I, Daley MJ, Shewale A, Pangrazzi MH, Hammond D, Olsen KM, DEFINE study group and the Discovery Research Network) Pharmacotherapy 2019 Mar;39(3):253-260 PMID: 30101412 SCOPUS ID: 2-s2.0-85054312441 08/14/2018       16 Citations
  • Clostridium difficile Exposures, Colonization, and the Microbiome: Implications for Prevention. (Revolinski SL, Munoz-Price LS) Infect Control Hosp Epidemiol 2018 May;39(5):596-602 PMID: 29553000 SCOPUS ID: 2-s2.0-85044227070 03/20/2018       7 Citations
  • A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community-acquired pneumonia. (Foolad F, Huang AM, Nguyen CT, Colyer L, Lim M, Grieger J, Li J, Revolinski S, Mack M, Gandhi T, Wainaina JN, Eschenauer G, Patel TS, Marshall VD, Nagel J) J Antimicrob Chemother 2018 May 01;73(5):1402-1407 PMID: 29462306 SCOPUS ID: 2-s2.0-85047020330 02/21/2018       27 Citations
  • Rapid diagnostics in infection prevention (Revolinski S, Huang AM, Gibble A) Infection Prevention: New Perspectives and Controversies 7 September 2017:297-305 SCOPUS ID: 2-s2.0-85034761271 09/07/2017    
  • Implementation of a clinical decision support alert for the management of Clostridium difficile infection (Revolinski S) Antibiotics 21 December 2015;4(4):667-674 SCOPUS ID: 2-s2.0-85007147464 12/21/2015       14 Citations
  • Last update: 01/13/2022